Skip to Main Content
We discovered some positive trends after analyzing the financial performance of the 16 largest, pure biopharmaceutical companies over the past 7 years.
From 2013 on, our findings show:
The negative impact from sales lost to patent expiration peaked in 2012 and will lessen.
The ratio of revenue from the pipeline and current portfolio compared to sales lost from patent expiry will improve.
Select companies are showing notably improved performance.
Investors are looking beyond the patent crisis and valuing companies that have clearly articulated a path to sustainable growth and are making substantial strategic and operational changes to achieve their growth objectives.
To see a snapshot of our key findings and learn the moves top industry players made to return to profitable growth, please scroll down.
December 20, 2012
Life Sciences Home
Beyond the Patent Cliff: Signs of Recovery for Biopharma
Skip Footer Links